Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Personalized Medicine in Neurodegenerative Diseases
share announcement

Personalized Medicine in Neurodegenerative Diseases

A special issue of Journal of Personalized Medicine (ISSN 2075-4426).

Deadline for manuscript submissions: closed (15 September 2022) | Viewed by 3049

Special Issue Editor

Dr. Valentina Bessi

E-Mail Website
Guest Editor
Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Azienda Ospedaliera-Universitaria Careggi, Florence, Italy
Interests: neurodegeneration; cognitive neuroscience; PET/CT; molecular imaging; neuroimaging
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Neurodegenerative diseases are a heterogeneous group of chronic disorders initiated through misfolded proteins forming neurotoxic substances that lead to a progressive loss of neuronal functions with variable clinical features, including memory loss, speech difficulties, and motor impairment. The neurodegenerative processes start decades before the appearance of clinical symptoms, and therefore, it is necessary to identify the pathological mechanisms as soon as possible, before the manifestation of clinical evidence. Neurodegenerative disease represents suitable models for taking full advantage of personalized medicine technologies applied to all stages of disease development. The availability of high technology incorporating machine learning processes has been substantial to understanding how genes, epigenetic modifications, and environmental factors can impact chronic disorders. This issue will provide updates on these emerging fields. In particular, papers investigating the role of current and future CSF and blood biomarkers, genetic factors involved in neurodegenerative disease, and molecular imaging biomarkers in the context of personalized medicine are requested.

Dr. Valentina Bessi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarkers 
  • Alzheimer’s disease 
  • frontotemporal degeneration 
  • Dementia 
  • neurodegeneration 
  • brain 
  • genetics 
  • personalized medicine 
  • motoneuron disease 
  • Parkinson’s disease

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

18 pages, 1809 KiB  
Review
iPSCs in Neurodegenerative Disorders: A Unique Platform for Clinical Research and Personalized Medicine
by Shashank Pandey, Michal Jirásko, Jan Lochman, Alexandr Chvátal, Magdalena Chottova Dvorakova and Radek Kučera
J. Pers. Med. 2022, 12(9), 1485; https://doi.org/10.3390/jpm12091485 - 10 Sep 2022
Cited by 8 | Viewed by 2577
Abstract
In the past, several animal disease models were developed to study the molecular mechanism of neurological diseases and discover new therapies, but the lack of equivalent animal models has minimized the success rate. A number of critical issues remain unresolved, such as high [...] Read more.
In the past, several animal disease models were developed to study the molecular mechanism of neurological diseases and discover new therapies, but the lack of equivalent animal models has minimized the success rate. A number of critical issues remain unresolved, such as high costs for developing animal models, ethical issues, and lack of resemblance with human disease. Due to poor initial screening and assessment of the molecules, more than 90% of drugs fail during the final step of the human clinical trial. To overcome these limitations, a new approach has been developed based on induced pluripotent stem cells (iPSCs). The discovery of iPSCs has provided a new roadmap for clinical translation research and regeneration therapy. In this article, we discuss the potential role of patient-derived iPSCs in neurological diseases and their contribution to scientific and clinical research for developing disease models and for developing a roadmap for future medicine. The contribution of humaniPSCs in the most common neurodegenerative diseases (e.g., Parkinson’s disease and Alzheimer’s disease, diabetic neuropathy, stroke, and spinal cord injury) were examined and ranked as per their published literature on PUBMED. We have observed that Parkinson’s disease scored highest, followed by Alzheimer’s disease. Furthermore, we also explored recent advancements in the field of personalized medicine, such as the patient-on-a-chip concept, where iPSCs can be grown on 3D matrices inside microfluidic devices to create an in vitro disease model for personalized medicine. Full article
(This article belongs to the Special Issue Personalized Medicine in Neurodegenerative Diseases)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop